Shingrix疫苗在免疫功能受损且水痘-带状疱疹病毒未感染儿童中的安全性、免疫原性与有效性
荷兰Wilhelmina儿童医院开展单中心真实世界回顾性队列研究,纳入10例接受免疫抑制治疗且水痘-带状疱疹病毒未感染的儿童(中位年龄2岁11个月),接种Shingrix疫苗后9例产生VZV特异性IgG抗体,观察到2例轻度突破性水痘感染,1例严重不良事件可能与合并病毒感染有关,中位随访7.6个月。
要点
- 10例免疫抑制且VZV未感染儿童接种Shingrix,9例产生VZV特异性IgG抗体。
- 仅接种1剂的1例患者仍为血清阴性。
- 观察到2例轻度突破性水痘感染,无并发症。
核心结论
- Shingrix在免疫功能受损儿童中显示可接受的安全性,除1例外均引发体液免疫应答,疫苗似乎提供针对水痘的保护,但观察到轻度突破性感染。
- 作者认为这是首份关于Shingrix用于VZV未感染、免疫功能受损儿童的报告。
研究设计与样本
- 单中心真实世界回顾性队列研究,在荷兰Wilhelmina儿童医院儿科风湿科开展。
- 纳入10例接受免疫抑制治疗且VZV未感染的儿童,中位年龄2岁11个月。
- 从首剂Shingrix接种至数据收集的中位随访期为7.6个月。
主要发现
- 10例中9例接种后产生VZV特异性IgG抗体,仅接种单剂的1例仍为血清阴性。
- 观察到2例轻度突破性水痘感染,无并发症。
- 记录到1例严重不良事件,可能归因于合并病毒感染而非疫苗本身。
关键数值与推荐
- 安全性依据接种后3个月内记录的不良事件评估。
- 免疫原性通过接种前后VZV IgG抗体水平检测评估。
- 有效性通过突破性水痘感染的发生及临床严重程度判定。
局限性
- 作者指出需要更大规模、更长随访的前瞻性研究来确认该脆弱人群的长期有效性和最佳接种策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pediatric patients with autoimmune and inflammatory diseases often require immunosuppressive therapy, which increases their susceptibility to infections, including varicella-zoster virus (VZV). While the live attenuated varicella vaccine is contraindicated in most immunocompromised children, the recombinant subunit vaccine, Shingrix, may offer an alternative preventive strategy. However, data on its safety, immunogenicity, and efficacy in pediatric VZV-naïve patients remain limited. OBJECTIVE: To evaluate the safety, immunogenicity, and efficacy of the Shingrix vaccine administered to VZV-naïve pediatric patients receiving immunosuppressive therapy. METHODS: We conducted a monocenter, real-world retrospective cohort study at the Pediatric Rheumatology Department of Wilhelmina Children's Hospital, Netherlands. Ten VZV-naïve pediatric patients (median age: 2 years 11 months) on immunosuppressive treatment who received the Shingrix vaccine were included. Safety was evaluated based on adverse events recorded within three months post-vaccination. Immunogenicity was assessed by measuring VZV IgG antibody levels pre- and post-vaccination. Efficacy was determined by the occurrence and clinical severity of breakthrough varicella infections. The median follow-up period from the first Shingrix dose to data collection was 7.6 months. RESULTS: Nine of ten patients developed VZV-specific IgG antibodies post-vaccination. One patient who received only a single dose remained seronegative. Two mild breakthrough varicella infections were observed without complications. One severe adverse event was recorded, likely attributable to concurrent viral infection rather than the vaccine itself. CONCLUSION: To our knowledge, this is the first report on the use of Shingrix in VZV-naïve, immunocompromised pediatric patients. Shingrix demonstrated an acceptable safety profile in immunocompromised pediatric patients and elicited a humoral immune response in all but one cases. The vaccine appeared to provide protection against varicella, although mild breakthrough infections were observed. Prospective studies with larger cohorts and longer follow-ups are warranted to confirm its long-term efficacy and optimal vaccination strategies in this vulnerable population.
引用
- Hamad Saied M, El Bied N, Khoury L, et al. Safety, immunogenicity and efficacy of the Shingrix vaccine in immunocompromised varicella zoster virus naïve pediatric patients. Vaccine. 2025. PMID: 40916263. doi:10.1016/j.vaccine.2025.127708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。